Design Therapeutics share price logo

Design Therapeutics

NASDAQ: DSGN

Small Cap

$10.63

+0.29

(+2.80%)

as on

Design Therapeutics Stock Performance

as on November 5, 2026 at 2:16 pm IST

  • Day's Low

    Day's High

    $10.31
    $10.79
    downward going graph

    3.01%

    Downside

    1.51%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $6.23
    $17.25
    downward going graph

    41.39%

    Downside

    62.28%

    Upside

    downward going graph

Design Therapeutics share price movements today

Previous Close
$10.34
Open
$10.65
Volume
414.2K
Market Cap
$647.1M
Day's Low - High
$10.31 - $10.79
52 Week Low - High
$6.23 - $17.25

Design Therapeutics Historical Returns

1 Month Return
-14.41 %
3 Month Return
-21.67 %
1 Year Return
+ 62.29 %
3 Year Return
+ 385.39 %
5 Year Return
-40.75 %

Design Therapeutics Stock Fundamentals & Key Indicators

Check Design Therapeutics market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$647.1M

EPS (TTM)

-1.18

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-8.76

Industry PE ratio

-6.15

PEG Ratio

1.57

EBITDA

-72.2M

Revenue (TTM)

-

Profit Margin

0.00%

Return On Equity TTM

-34.03%

Design Therapeutics vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Design Therapeutics with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Hold$647.1M-40.75%-8.760.00%0.00%
Neutral$91.2B9.03%-28.63-12.57%0.00%
StrongBuy$141.7B192.56%32.2786.04%0.00%
Buy$99.4B52.18%20.7385.77%0.38%

Stock Returns calculator for Design Therapeutics Stock including INR - Dollar returns

The Design Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

Design Therapeutics investment value today

Current value as on today

₹1,73,096

Returns

₹73,096

(+73.1%)

Returns from Design Therapeutics Stock

₹62,290 (+62.29%)

Dollar Impact

₹10,806 (+10.81%)

Analyst Recommendation on Design Therapeutics Stock

Based on 8 analysts

HOLD

0.00%

Buy

62.50%

Hold

37.50%

Sell

Based on 8 analysts, 62.5% of analysts recommend a 'HOLD' rating for Design Therapeutics. Average target price of $21.71

Design Therapeutics Share Price Target

Get share price movements and forecasts by analysts on Design Therapeutics.

What analysts predicted

51.04%UPSIDE

Target Price

$21.71

Current Price

$10.63

Analyzed by

8 Analysts

Target

$21.71

Design Therapeutics target price $21.71, a slight upside of 51.04% compared to current price of $10.63. According to 8 analysts rating.

Indian Investors' Interest in Design Therapeutics Stock

Search interest for Design Therapeutics Stock has decreased by -70% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-70% versus previous 30 day period

Design Therapeutics Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
-
-
-
-
-
-
-
-
-
-
Gross Profit
0
0
-
-
-
-
-
-
-
-
Operating Income
-14
-15
-16
-16
-20
-21
-19
-18
-19
-22
EBITDA
-10
-11
-12
-13
-17
-18
-16
-15
-17
-22
Interest Expense
-
-
-
-
-
-
-
-
-
-
Depreciation
0
0
0
0
0
0
0
0
0
0
Income Before Tax
-11
-11
-13
-13
-17
-19
-16
-15
-17
-20
Income Tax Expense
-
-
-
-
-
-
-
-
-
-
Net Income
-11
-11
-13
-13
-17
-19
-16
-15
-17
-20
Net Profit Margin
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%

Design Therapeutics Annual Profit & Loss

All numbers in Millions USD

Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
0
-
-
-
-
-
-
Gross Profit
0
0
-
0
0
-
-
Operating Income
-1
-8
-35
-67
-78
-62
-79
EBITDA
0
-8
-35
-62
-66
-48
-69
Interest Expense
-
-
-
-
-
-
-
Depreciation
1
0
0
0
0
0
0
Income Before Tax
-2
-8
-35
-63
-66
-49
-69
Income Tax Expense
-
-
-
-
-
-
-
Net Income
-2
-8
-35
-63
-66
-49
-69
Net Profit Margin
-98.32%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%

Design Therapeutics Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
-11
-11
-13
-13
-17
-19
-16
-15
-17
-20
Operating Cash Flow
-12
-11
-9
-9
-16
-14
-11
-11
-16
-15
Investing Cash Flow
20
27
-5
1
7
20
6
-11
-7
15
Financing Cash Flow
0
0
0
0
0
0
0
25
19
0
Change in Cash
8
16
-15
-7
-8
6
-4
1
-4
0

Design Therapeutics Annual Cash Flow

All numbers in Millions USD

Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-2
-8
-35
-63
-66
-49
-69
Operating Cash Flow
0
-8
-29
-51
-58
-43
-54
Investing Cash Flow
-
-33
-53
-220
52
43
22
Financing Cash Flow
0
44
379
0
0
0
25
Change in Cash
0
2
296
-272
-5
1
-5

Global Institutional Holdings in Design Therapeutics

Check out the Institutions with significant holdings in Design Therapeutics.

Funds
Holdings
Simeon George
10.43%
Peter Kolchinsky
4.75%
Felix Baker
4.28%
Steve Weber
4.25%
BlackRock, Inc.
4.25%

Insights on Design Therapeutics

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 1 year, DSGN stock has moved up by 62.3%

  • imgPOSITIVE IMPACT

    Best in 3 Years

    img

    In the last 3 years, DSGN has outperformed top 5 stocks with highest market-cap in its industry

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Moderna, Inc. Common Stock has given 996.7% return, outperforming this stock by 934.4%

About Design Therapeutics

Design Therapeutics, Inc. is a biopharmaceutical company in the preclinical phase that focuses on creating treatments for genetic conditions stemming from nucleotide repeat expansions. Its current pipeline targets Friedreich's Ataxia (FA), a severe, progressive, monogenic, and autosomal recessive disease. FA primarily impairs mitochondrial function across various organ systems, resulting in neurological, cardiac, and metabolic complications. Another significant area of development is Myotonic Dystrophy Type-1 (DM1). This is a progressive, dominantly inherited monogenic neuromuscular illness that impacts skeletal muscle, the heart, brain, and other bodily systems. Beyond these, the company is advancing its GeneTAC product candidate platform to address an array of other monogenic conditions caused by nucleotide repeat expansions. These include Fragile X syndrome, various spinocerebellar ataxias, amyotrophic lateral sclerosis (ALS), frontotemporal dementia, Huntington's disease, and spinobulbar muscular atrophy. Established in 2017, Design Therapeutics, Inc. maintains its headquarters in Carlsbad, California.
OrganisationDesign Therapeutics
Headquarters6005 Hidden Valley Road, Carlsbad, CA, 92011, US
IndustryBiotechnology
CEOPratik Shah

Key Management of Design Therapeutics

Name

Title

Mr. Mustapha Parekh

General Counsel

Dr. Tadimeti S. Rao Ph.D.

Chief Scientific Officer

Mr. Jim Kerr

Chief of Manufacturing & Product Development

Mr. Pratik Shah Ph.D.

Co-Founder, President, CEO, Principal Financial Officer & Executive Chairperson

Dr. Sean Jeffries Ph.D.

Chief Operating Officer

Dr. Aseem Z. Ansari Ph.D.

Co-Founder & Scientific Advisor

Dr. Chengzhi Zhang Ph.D.

Chief Chemist

Dr. Chris M. Storgard M.D.

Chief Medical Officer

Ms. Julie D. Burgess CPA

Chief Accounting Officer

Mr. Doane Chilcoat Ph.D.

Chief Technology Officer

FAQs

What is Design Therapeutics share price today?

Design Therapeutics share price today is $10.63 as on at the close of the market. Design Therapeutics share today touched a day high of $10.79 and a low of $10.31.

What is the 52 week high and 52 week low for Design Therapeutics share?

Design Therapeutics share touched a 52 week high of $17.25 on and a 52 week low of $6.23 on . Design Therapeutics stock price today i.e. is closed at $10.63,which is 38.38% down from its 52 week high and 70.63% up from its 52 week low.

What is Design Therapeutics's market capitalisation today?

Design Therapeutics market capitalisation is $0.00T as on .

How to invest in Design Therapeutics Stock (DSGN) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Design Therapeutics on INDmoney app. Click on Buy button.

What is the minimum amount required to buy Design Therapeutics Stock (DSGN) from India?

Indian investors can start investing in Design Therapeutics (DSGN) shares with as little as ₹94.63999938964844 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹946.40 in Design Therapeutics stock (as per the Rupee-Dollar exchange rate as on ). Based on Design Therapeutics share’s latest price of $10.63 as on November 5, 2026 at 8:46 am IST, you will get 0.9407 shares of Design Therapeutics. Learn more about fractional shares .

What are the returns that Design Therapeutics has given to Indian investors in the last 5 years?

Design Therapeutics stock has given -40.75% share price returns and 27.31% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?